≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other and unspecified syphilis, including avohilmo

Endpoint Browser PheWeb

AB1_SYPHILIS_NOS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — A53
  • Hospital discharge: ICD-10 — A53
  • Hospital discharge: ICD-9 — 097
  • Hospital discharge: ICD-8 — 097
  • Cause of death: ICD-10 — A53
  • Cause of death: ICD-9 — 097
  • Cause of death: ICD-8 — 097

3 out of 7 registries used, show all original rules.

149

4. Check minimum number of events

None

149

5. Include endpoints

None

149

6. Filter based on genotype QC (FinnGen only)

129

Control definitions (FinnGen only)

Control exclude
AB1_SEXUAL_TRANSMISSION

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF13

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 129 31 98
Unadjusted period prevalence (%) 0.04 0.01 0.04
Median age at first event (years) 45.22 39.60 46.99

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
149
Matched controls
1490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A53.9
ICD-10 Finland
Syphilis, unspecified
+∞
126.8
103
*
Z11.3
ICD-10 Finland
Special screening examination for infections with a predominantly sexual mode of transmission
32.1
98.0
77
48
WW200
NOMESCO Finland
Immunization
36.0
72.2
49
20
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
127.5
43.6
45
5
A56.3
ICD-10 Finland
Chlamydial infection of anus and rectum
+∞
40.5
37
*
Y25
ICPC
Fear sexually transm disease male
13.1
35.1
38
38
A51.0
ICD-10 Finland
Primary genital syphilis
+∞
34.8
32
*
A53.0
ICD-10 Finland
Latent syphilis, unspecified as early or late
+∞
33.6
31
*
B24
ICD-10 Finland
Unspecified human immunodeficiency virus [HIV] disease
74.4
22.6
25
*
A54.6
ICD-10 Finland
Gonococcal infection of anus and rectum
+∞
22.5
21
*
Z25.1
ICD-10 Finland
Need for immunization against influenza
10.3
21.3
26
30
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
7.0
20.3
36
65
A51.9
ICD-10 Finland
Early syphilis, unspecified
+∞
20.3
19
*
A54.5
ICD-10 Finland
Gonococcal pharyngitis
229.2
20.1
20
*
A51.3
ICD-10 Finland
Secondary syphilis of skin and mucous membranes
+∞
19.2
18
*
Z3231
NOMESCO Finland
Registered nurse
4.6
19.0
71
245
Z2221
NOMESCO Finland
Medical doctor
4.5
17.7
64
214
Z71.8
ICD-10 Finland
Other specified counselling
4.2
16.8
80
324
Y70
ICPC
Syphilis male
+∞
15.9
15
*
A56.0
ICD-10 Finland
Chlamydial infection of lower genitourinary tract
26.9
15.6
21
9
Z21
ICD-10 Finland
Asymptomatic human immunodeficiency virus [HIV] infection status
82.6
13.8
15
*
A54.0
ICD-10 Finland
Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess
+∞
13.8
13
*
09710
ICD-8 Finland
Other syphilis and not specified, Latent syphilis, unspecified
+∞
11.6
11
*
A63.0
ICD-10 Finland
Anogenital (venereal) warts
15.6
11.3
18
13
Z29.2
ICD-10 Finland
Other prophylactic chemotherapy
118.0
10.6
11
*
B23.8
ICD-10 Finland
HIV disease resulting in other specified conditions
106.5
9.5
10
*
B23.0
ICD-10 Finland
Acute HIV infection syndrome
+∞
9.5
9
*
UJF30
NOMESCO Finland
Ileoscopy through colon
4.5
9.0
24
61
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.2
8.6
43
169
A56.4
ICD-10 Finland
Chlamydial infection of pharynx
+∞
8.4
8
*
A52.9
ICD-10 Finland
Late syphilis, unspecified
+∞
8.4
8
*
A52.1
ICD-10 Finland
Symptomatic neurosyphilis
+∞
8.4
8
*
TAB00
NOMESCO Finland
Lumbar puncture
6.6
8.0
20
34
WX110, ,
SPAT
4.7
8.0
20
48
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.7
7.5
57
278
Z76.0
ICD-10 Finland
Issue of repeat prescription
2.7
7.5
54
257
J01MA02
ATC
ciprofloxacin; systemic
2.6
7.4
65
341
Y71
ICPC
Gonorrhoea male
+∞
7.3
7
*
A53
ICD-10 Finland
Other and unspecified syphilis
+∞
7.3
7
*
D01
ICPC
Abdominal pain/cramps general
3.3
6.6
27
93
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.7
6.5
41
181
S02.51
ICD-10 Finland
Fracture of tooth, open
3.8
6.4
21
62
ZX114
NOMESCO Finland
Intramuscular
11.8
6.4
11
10
A51.5
ICD-10 Finland
Early syphilis, latent
+∞
6.3
6
*
A52.3
ICD-10 Finland
Neurosyphilis, unspecified
+∞
6.3
6
*
A52.2
ICD-10 Finland
Asymptomatic neurosyphilis
+∞
6.3
6
*
A54.9
ICD-10 Finland
Gonococcal infection, unspecified
+∞
6.3
6
*
Z2446
NOMESCO Finland
Social worker
4.1
6.0
17
45

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.3e+00
2.0e+00
3.8e+00
—
4.6e+00
2.7e+00
2.8e+00
cases:38.35%
controls:6.09%
cases:17.29%
controls:2.78%
cases:16.54%
controls:0.45%
—
—
cases:43.18%
controls:0.75%
cases:34.88%
controls:3.40%
cases:47.47%
controls:5.24%
51
81
82
1249
23
37
110
1293
22
6
111
1324
—
57
10
75
1320
45
44
84
1251
47
54
52
976
Infectious Disease
44 [38004484]
3.2e+00
3.5e+00
—
1.0e+50
1.0e+50
4.5e+00
3.7e+00
cases:29.32%
controls:1.73%
cases:27.07%
controls:1.05%
—
—
cases:29.32%
controls:0.00%
cases:21.21%
controls:0.00%
cases:41.86%
controls:0.77%
cases:44.44%
controls:1.94%
39
23
94
1307
36
14
97
1316
—
39
0
94
1330
28
0
104
1330
54
10
75
1285
44
20
55
1010
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
2.3e+00
2.7e+00
—
—
—
3.0e+00
3.0e+00
cases:18.80%
controls:2.26%
cases:14.29%
controls:1.13%
—
—
—
—
—
—
cases:17.83%
controls:1.08%
cases:29.29%
controls:2.04%
25
30
108
1300
19
15
114
1315
—
—
—
23
14
106
1281
29
21
70
1009
Outpatient Visit
OP [9202]
6.8e-01
5.9e-01
1.5e+00
4.7e+00
1.9e+00
1.5e+00
1.1e+00
cases:80.45%
controls:67.52%
cases:57.89%
controls:43.16%
cases:28.57%
controls:7.89%
cases:30.08%
controls:0.38%
cases:38.64%
controls:8.35%
cases:75.97%
controls:40.23%
cases:88.89%
controls:72.04%
107
898
26
432
77
574
56
756
38
105
95
1225
40
5
93
1325
51
111
81
1219
98
521
31
774
88
742
11
288
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
1.6e+00
2.3e+00
—
—
2.3e+00
2.3e+00
2.2e+00
cases:21.05%
controls:5.04%
cases:18.80%
controls:2.18%
—
—
—
—
cases:4.55%
controls:0.45%
cases:19.38%
controls:2.32%
cases:28.28%
controls:4.37%
28
67
105
1263
25
29
108
1301
—
—
6
6
126
1324
25
30
104
1265
28
45
71
985
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.8e+00
2.3e+00
—
—
—
3.1e+00
3.3e+00
cases:12.03%
controls:2.18%
cases:12.78%
controls:1.43%
—
—
—
—
—
—
cases:16.28%
controls:0.85%
cases:30.30%
controls:1.55%
16
29
117
1301
17
19
116
1311
—
—
—
21
11
108
1284
30
16
69
1014
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
2.1e+00
2.5e+00
—
—
—
3.0e+00
2.9e+00
cases:20.30%
controls:2.93%
cases:15.04%
controls:1.43%
—
—
—
—
—
—
cases:18.60%
controls:1.16%
cases:29.29%
controls:2.14%
27
39
106
1291
20
19
113
1311
—
—
—
24
15
105
1280
29
22
70
1008
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
1.7e+00
2.2e+00
—
—
2.2e+00
2.3e+00
2.2e+00
cases:24.06%
controls:5.71%
cases:18.80%
controls:2.41%
—
—
—
—
cases:4.55%
controls:0.53%
cases:20.93%
controls:2.70%
cases:30.30%
controls:4.66%
32
76
101
1254
25
32
108
1298
—
—
6
7
126
1323
27
35
102
1260
30
48
69
982
Differential panel, method unspecified - Blood
69738-3 [42870588]
9.0e-01
1.5e+00
2.3e+00
—
2.2e+00
1.7e+00
1.8e+00
cases:15.79%
controls:7.07%
cases:16.54%
controls:4.44%
cases:5.26%
controls:0.53%
—
—
cases:5.30%
controls:0.60%
cases:17.83%
controls:3.78%
cases:32.32%
controls:7.28%
21
94
112
1236
22
59
111
1271
7
7
126
1323
—
7
8
125
1322
23
49
106
1246
32
75
67
955
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
8.8e-01
1.2e+00
2.3e+00
—
2.4e+00
1.7e+00
1.7e+00
cases:21.80%
controls:10.38%
cases:18.05%
controls:6.39%
cases:8.27%
controls:0.90%
—
—
cases:8.33%
controls:0.83%
cases:23.26%
controls:5.33%
cases:41.41%
controls:11.46%
29
138
104
1192
24
85
109
1245
11
12
122
1318
—
11
11
121
1319
30
69
99
1226
41
118
58
912
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
2.0e+00
2.8e+00
1.0e+50
—
1.0e+50
2.5e+00
2.8e+00
cases:19.55%
controls:3.16%
cases:13.53%
controls:0.98%
cases:9.02%
controls:0.00%
—
—
cases:5.30%
controls:0.00%
cases:17.05%
controls:1.70%
cases:38.38%
controls:3.59%
26
42
107
1288
18
13
115
1317
12
0
121
1330
—
7
0
125
1330
22
22
107
1273
38
37
61
993
Monocytes/Leukocytes in Blood
26485-3 [3019069]
9.0e-01
1.2e+00
2.3e+00
—
2.3e+00
1.7e+00
1.7e+00
cases:21.80%
controls:10.23%
cases:18.05%
controls:6.24%
cases:8.27%
controls:0.90%
—
—
cases:8.33%
controls:0.90%
cases:23.26%
controls:5.41%
cases:41.41%
controls:11.36%
29
136
104
1194
24
83
109
1247
11
12
122
1318
—
11
12
121
1318
30
70
99
1225
41
117
58
913
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.1e-01
1.2e+00
2.3e+00
—
2.3e+00
1.6e+00
1.7e+00
cases:21.80%
controls:10.08%
cases:18.05%
controls:6.17%
cases:8.27%
controls:0.90%
—
—
cases:8.33%
controls:0.90%
cases:23.26%
controls:5.56%
cases:41.41%
controls:11.46%
29
134
104
1196
24
82
109
1248
11
12
122
1318
—
11
12
121
1318
30
72
99
1223
41
118
58
912
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.0e-01
1.2e+00
2.3e+00
—
2.3e+00
1.6e+00
1.7e+00
cases:21.80%
controls:10.15%
cases:18.05%
controls:6.24%
cases:8.27%
controls:0.90%
—
—
cases:8.33%
controls:0.90%
cases:23.26%
controls:5.56%
cases:41.41%
controls:11.46%
29
135
104
1195
24
83
109
1247
11
12
122
1318
—
11
12
121
1318
30
72
99
1223
41
118
58
912
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
8.5e-01
1.2e+00
2.3e+00
—
2.3e+00
1.7e+00
1.6e+00
cases:21.80%
controls:10.68%
cases:18.05%
controls:6.47%
cases:8.27%
controls:0.90%
—
—
cases:8.33%
controls:0.90%
cases:23.26%
controls:5.41%
cases:40.40%
controls:11.65%
29
142
104
1188
24
86
109
1244
11
12
122
1318
—
11
12
121
1318
30
70
99
1225
40
120
59
910
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
2.2e+00
2.5e+00
1.0e+50
—
—
2.5e+00
2.7e+00
cases:14.29%
controls:1.88%
cases:7.52%
controls:0.68%
cases:6.02%
controls:0.00%
—
—
—
—
cases:11.63%
controls:1.08%
cases:27.27%
controls:2.52%
19
25
114
1305
10
9
123
1321
8
0
125
1330
—
—
15
14
114
1281
27
26
72
1004
Basophils [#/volume] in Blood
26444-0 [3006315]
8.3e-01
1.1e+00
2.1e+00
—
2.4e+00
1.5e+00
1.5e+00
cases:21.80%
controls:10.83%
cases:18.80%
controls:7.22%
cases:8.27%
controls:1.05%
—
—
cases:9.09%
controls:0.90%
cases:23.26%
controls:6.33%
cases:40.40%
controls:12.62%
29
144
104
1186
25
96
108
1234
11
14
122
1316
—
12
12
120
1318
30
82
99
1213
40
130
59
900
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.9e-01
1.0e+00
2.1e+00
—
2.4e+00
1.5e+00
1.5e+00
cases:21.05%
controls:10.75%
cases:18.05%
controls:7.22%
cases:8.27%
controls:1.05%
—
—
cases:9.09%
controls:0.90%
cases:23.26%
controls:6.33%
cases:40.40%
controls:12.72%
28
143
105
1187
24
96
109
1234
11
14
122
1316
—
12
12
120
1318
30
82
99
1213
40
131
59
899
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.9e-01
1.1e+00
2.1e+00
—
2.3e+00
1.5e+00
1.5e+00
cases:21.80%
controls:11.20%
cases:18.80%
controls:7.37%
cases:8.27%
controls:1.05%
—
—
cases:8.33%
controls:0.90%
cases:23.26%
controls:6.41%
cases:40.40%
controls:13.01%
29
149
104
1181
25
98
108
1232
11
14
122
1316
—
11
12
121
1318
30
83
99
1212
40
134
59
896
Eosinophils [#/volume] in Blood
26449-9 [3013115]
8.5e-01
1.1e+00
2.0e+00
—
2.2e+00
1.5e+00
1.6e+00
cases:22.56%
controls:11.05%
cases:18.80%
controls:7.44%
cases:8.27%
controls:1.20%
—
—
cases:8.33%
controls:0.98%
cases:23.26%
controls:6.49%
cases:42.42%
controls:13.50%
30
147
103
1183
25
99
108
1231
11
16
122
1314
—
11
13
121
1317
30
84
99
1211
42
139
57
891
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
1.8e+00
2.7e+00
—
—
—
2.3e+00
2.1e+00
cases:18.80%
controls:3.61%
cases:16.54%
controls:1.28%
—
—
—
—
—
—
cases:13.18%
controls:1.47%
cases:24.24%
controls:3.88%
25
48
108
1282
22
17
111
1313
—
—
—
17
19
112
1276
24
40
75
990
Normoblasts [#/volume] in Blood
715-3 [3021589]
9.4e-01
9.5e-01
2.0e+00
—
1.5e+00
1.4e+00
1.6e+00
cases:21.05%
controls:9.47%
cases:15.79%
controls:6.77%
cases:8.27%
controls:1.20%
—
—
cases:6.82%
controls:1.58%
cases:20.16%
controls:5.79%
cases:40.40%
controls:11.75%
28
126
105
1204
21
90
112
1240
11
16
122
1314
—
9
21
123
1309
26
75
103
1220
40
121
59
909
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
3.3e+00
—
1.0e+50
1.0e+50
1.0e+50
5.0e+00
—
cases:15.79%
controls:0.68%
—
—
cases:36.09%
controls:0.00%
cases:9.77%
controls:0.00%
cases:15.15%
controls:0.00%
cases:41.09%
controls:0.46%
—
—
21
9
112
1321
—
48
0
85
1330
13
0
120
1330
20
0
112
1330
53
6
76
1289
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.1e-01
9.1e-01
1.9e+00
—
1.7e+00
1.4e+00
1.5e+00
cases:24.06%
controls:12.33%
cases:18.80%
controls:8.50%
cases:8.27%
controls:1.28%
—
—
cases:9.09%
controls:1.73%
cases:24.03%
controls:7.34%
cases:43.43%
controls:14.76%
32
164
101
1166
25
113
108
1217
11
17
122
1313
—
12
23
120
1307
31
95
98
1200
43
152
56
878
Leukocytes [#/volume] in Urine
30405-5 [3018095]
9.7e-01
1.4e+00
2.3e+00
—
—
1.6e+00
1.5e+00
cases:16.54%
controls:6.99%
cases:11.28%
controls:3.08%
cases:3.76%
controls:0.38%
—
—
—
—
cases:12.40%
controls:2.70%
cases:27.27%
controls:7.38%
22
93
111
1237
15
41
118
1289
5
5
128
1325
—
—
16
35
113
1260
27
76
72
954
Short blood count panel - Blood
55429-5 [40758558]
1.5e+00
1.3e+00
—
—
2.7e+00
1.4e+00
2.3e+00
cases:17.29%
controls:4.51%
cases:7.52%
controls:2.11%
—
—
—
—
cases:6.06%
controls:0.45%
cases:8.53%
controls:2.16%
cases:31.31%
controls:4.56%
23
60
110
1270
10
28
123
1302
—
—
8
6
124
1324
11
28
118
1267
31
47
68
983
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
8.6e-01
1.5e+00
2.2e+00
—
1.7e+00
1.8e+00
1.5e+00
cases:26.32%
controls:13.08%
cases:20.30%
controls:5.56%
cases:7.52%
controls:0.90%
—
—
cases:4.55%
controls:0.83%
cases:24.81%
controls:5.33%
cases:50.51%
controls:18.16%
35
174
98
1156
27
74
106
1256
10
12
123
1318
—
6
11
126
1319
32
69
97
1226
50
187
49
843
Fear sexually transm disease male
Y25 [2002001393]
2.5e+00
2.2e+00
—
—
—
3.1e+00
2.2e+00
cases:9.77%
controls:0.90%
cases:3.76%
controls:0.45%
—
—
—
—
—
—
cases:9.30%
controls:0.46%
cases:8.08%
controls:0.97%
13
12
120
1318
5
6
128
1324
—
—
—
12
6
117
1289
8
10
91
1020
Medical doctor
Z2221 [2001311556]
1.3e+00
1.9e+00
—
—
—
2.1e+00
2.3e+00
cases:13.53%
controls:4.14%
cases:8.27%
controls:1.28%
—
—
—
—
—
—
cases:7.75%
controls:1.00%
cases:18.18%
controls:2.23%
18
55
115
1275
11
17
122
1313
—
—
—
10
13
119
1282
18
23
81
1007
Laboratory Visit
OMOP4822461 [32036]
7.9e-02
4.0e-01
1.9e+00
3.8e+00
1.2e+00
7.3e-01
3.1e-01
cases:45.86%
controls:43.91%
cases:47.37%
controls:37.52%
cases:45.86%
controls:11.65%
cases:18.80%
controls:0.53%
cases:28.79%
controls:10.90%
cases:56.59%
controls:38.61%
cases:71.72%
controls:64.95%
61
584
72
746
63
499
70
831
61
155
72
1175
25
7
108
1323
38
145
94
1185
73
500
56
795
71
669
28
361
Emergency Room Visit
ER [9203]
6.9e-01
6.5e-01
2.7e+00
—
1.9e+00
1.1e+00
1.0e+00
cases:45.86%
controls:29.85%
cases:18.05%
controls:10.30%
cases:15.04%
controls:1.13%
—
—
cases:8.33%
controls:1.28%
cases:22.48%
controls:9.19%
cases:51.52%
controls:27.48%
61
397
72
933
24
137
109
1193
20
15
113
1315
—
11
17
121
1313
29
119
100
1176
51
283
48
747
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
6.7e-01
1.3e+00
2.4e+00
—
—
1.7e+00
1.8e+00
cases:13.53%
controls:7.44%
cases:12.78%
controls:3.76%
cases:6.77%
controls:0.68%
—
—
—
—
cases:17.05%
controls:3.71%
cases:37.37%
controls:8.64%
18
99
115
1231
17
50
116
1280
9
9
124
1321
—
—
22
48
107
1247
37
89
62
941
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.4e-01
1.1e+00
1.9e+00
—
—
1.3e+00
1.7e+00
cases:18.05%
controls:8.65%
cases:14.29%
controls:5.49%
cases:6.02%
controls:0.90%
—
—
—
—
cases:15.50%
controls:4.79%
cases:43.43%
controls:11.84%
24
115
109
1215
19
73
114
1257
8
12
125
1318
—
—
20
62
109
1233
43
122
56
908
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1.4e+00
—
—
—
—
2.1e+00
3.0e+00
cases:8.27%
controls:2.26%
—
—
—
—
—
—
—
—
cases:6.20%
controls:0.77%
cases:24.24%
controls:1.55%
11
30
122
1300
—
—
—
—
8
10
121
1285
24
16
75
1014
Case Management Agency
251B00000X [38004193]
3.1e-02
2.6e-01
1.1e+00
4.0e+00
1.2e+00
4.6e-01
4.3e-01
cases:68.42%
controls:67.74%
cases:65.41%
controls:59.32%
cases:47.37%
controls:22.86%
cases:43.61%
controls:1.43%
cases:49.24%
controls:22.56%
cases:72.87%
controls:63.01%
cases:87.88%
controls:82.52%
91
901
42
429
87
789
46
541
63
304
70
1026
58
19
75
1311
65
300
67
1030
94
816
35
479
87
850
12
180
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.1e+00
2.1e+00
—
—
—
1.8e+00
1.3e+00
cases:18.80%
controls:7.29%
cases:16.54%
controls:2.41%
—
—
—
—
—
—
cases:17.83%
controls:3.63%
cases:21.21%
controls:6.70%
25
97
108
1233
22
32
111
1298
—
—
—
23
47
106
1248
21
69
78
961
sildenafil; oral
G04BE03 [21602648]
1.3e+00
1.6e+00
2.2e+00
—
—
1.4e+00
1.4e+00
cases:15.04%
controls:4.66%
cases:14.29%
controls:3.23%
cases:3.76%
controls:0.45%
—
—
—
—
cases:13.18%
controls:3.55%
cases:25.25%
controls:7.57%
20
62
113
1268
19
43
114
1287
5
6
128
1324
—
—
17
46
112
1249
25
78
74
952
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.6e-01
6.4e-01
1.1e+00
2.7e+00
8.8e-01
8.5e-01
6.4e-01
cases:41.35%
controls:32.93%
cases:36.09%
controls:22.86%
cases:13.53%
controls:4.96%
cases:5.26%
controls:0.38%
cases:11.36%
controls:5.04%
cases:41.09%
controls:22.93%
cases:65.66%
controls:50.29%
55
438
78
892
48
304
85
1026
18
66
115
1264
7
5
126
1325
15
67
117
1263
53
297
76
998
65
518
34
512
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.3e+00
—
—
—
—
2.2e+00
1.5e+00
cases:11.28%
controls:3.46%
—
—
—
—
—
—
—
—
cases:7.75%
controls:0.93%
cases:14.14%
controls:3.50%
15
46
118
1284
—
—
—
—
10
12
119
1283
14
36
85
994
Treatment of a patient needing special arrangements
WYA30 [2001310874]
2.1e+00
—
—
—
—
—
2.7e+00
cases:6.02%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:16.16%
controls:1.26%
8
10
125
1320
—
—
—
—
—
16
13
83
1017
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
4.9e-01
9.2e-01
1.7e+00
—
9.9e-01
1.1e+00
1.1e+00
cases:33.08%
controls:23.23%
cases:33.83%
controls:16.92%
cases:15.79%
controls:3.38%
—
—
cases:9.85%
controls:3.91%
cases:36.43%
controls:16.45%
cases:60.61%
controls:34.95%
44
309
89
1021
45
225
88
1105
21
45
112
1285
—
13
52
119
1278
47
213
82
1082
60
360
39
670
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
1.1e+00
1.5e+00
—
—
—
2.0e+00
1.1e+00
cases:9.77%
controls:3.53%
cases:8.27%
controls:2.03%
—
—
—
—
—
—
cases:11.63%
controls:1.78%
cases:18.18%
controls:6.60%
13
47
120
1283
11
27
122
1303
—
—
—
15
23
114
1272
18
68
81
962
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.9e-01
7.9e-01
1.3e+00
—
1.5e+00
1.0e+00
1.2e+00
cases:24.06%
controls:16.32%
cases:21.80%
controls:11.20%
cases:6.02%
controls:1.65%
—
—
cases:9.09%
controls:2.18%
cases:23.26%
controls:9.96%
cases:49.49%
controls:23.40%
32
217
101
1113
29
149
104
1181
8
22
125
1308
—
12
29
120
1301
30
129
99
1166
49
241
50
789
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.4e-01
7.2e-01
1.6e+00
—
1.1e+00
8.9e-01
6.3e-01
cases:36.09%
controls:28.65%
cases:32.33%
controls:18.87%
cases:15.04%
controls:3.61%
—
—
cases:9.85%
controls:3.46%
cases:36.43%
controls:19.00%
cases:59.60%
controls:43.88%
48
381
85
949
43
251
90
1079
20
48
113
1282
—
13
46
119
1284
47
246
82
1049
59
452
40
578
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.6e-01
8.0e-01
1.4e+00
—
1.0e+00
1.0e+00
9.8e-01
cases:33.08%
controls:23.76%
cases:30.83%
controls:16.62%
cases:11.28%
controls:3.16%
—
—
cases:9.09%
controls:3.53%
cases:34.11%
controls:15.44%
cases:57.58%
controls:33.79%
44
316
89
1014
41
221
92
1109
15
42
118
1288
—
12
47
120
1283
44
200
85
1095
57
348
42
682
Venereal disease screening
171128005 [4064905]
4.1e+00
—
1.0e+50
—
1.0e+50
—
—
cases:21.05%
controls:0.45%
—
—
cases:7.52%
controls:0.00%
—
—
cases:8.33%
controls:0.00%
—
—
—
—
28
6
105
1324
—
10
0
123
1330
—
11
0
121
1330
—
—
One hour or less
ZXE00 [2001311394]
8.7e-01
1.5e+00
—
—
—
2.6e+00
1.4e+00
cases:9.77%
controls:4.36%
cases:4.51%
controls:1.05%
—
—
—
—
—
—
cases:6.98%
controls:0.54%
cases:13.13%
controls:3.50%
13
58
120
1272
6
14
127
1316
—
—
—
9
7
120
1288
13
36
86
994
Scheduled procedure
ZXD10 [2001311387]
8.0e-01
—
—
—
—
2.3e+00
1.6e+00
cases:7.52%
controls:3.53%
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.39%
cases:11.11%
controls:2.43%
10
47
123
1283
—
—
—
—
5
5
124
1290
11
25
88
1005
Supplier / Service Provider
OMOP5117446 [33004]
-4.8e-01
-4.5e-01
—
—
—
—
3.6e+00
cases:19.55%
controls:28.20%
cases:5.26%
controls:8.05%
—
—
—
—
—
—
—
—
cases:22.22%
controls:0.78%
26
375
107
955
7
107
126
1223
—
—
—
—
22
8
77
1022
Inpatient Hospital
21 [8717]
8.6e-02
0.0e+00
1.4e+00
1.0e+50
2.1e+00
9.4e-01
4.3e-01
cases:23.31%
controls:21.80%
cases:6.77%
controls:6.77%
cases:3.76%
controls:0.98%
cases:12.03%
controls:0.00%
cases:7.58%
controls:0.98%
cases:14.73%
controls:6.33%
cases:26.26%
controls:18.83%
31
290
102
1040
9
90
124
1240
5
13
128
1317
16
0
117
1330
10
13
122
1317
19
82
110
1213
26
194
73
836
Telehealth
OMOP5556618 [722455]
5.2e-01
8.2e-01
1.8e+00
1.0e+50
9.5e-01
1.2e+00
4.4e-01
cases:30.83%
controls:20.90%
cases:16.54%
controls:8.05%
cases:7.52%
controls:1.28%
cases:6.02%
controls:0.00%
cases:3.79%
controls:1.50%
cases:19.38%
controls:6.80%
cases:30.30%
controls:21.94%
41
278
92
1052
22
107
111
1223
10
17
123
1313
8
0
125
1330
5
20
127
1310
25
88
104
1207
30
226
69
804
Internal Medicine
11 [38004456]
3.8e-01
3.8e-01
2.1e+00
—
—
9.4e-01
5.0e-01
cases:23.31%
controls:17.14%
cases:8.27%
controls:5.79%
cases:4.51%
controls:0.60%
—
—
—
—
cases:13.95%
controls:5.95%
cases:24.24%
controls:16.31%
31
228
102
1102
11
77
122
1253
6
8
127
1322
—
—
18
77
111
1218
24
168
75
862
Other specified counselling
Z71.8 [45581061]
9.5e-01
1.4e+00
—
—
—
1.5e+00
1.3e+00
cases:10.53%
controls:4.36%
cases:6.77%
controls:1.80%
—
—
—
—
—
—
cases:10.08%
controls:2.39%
cases:22.22%
controls:6.99%
14
58
119
1272
9
24
124
1306
—
—
—
13
31
116
1264
22
72
77
958
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
8.6e-01
1.3e+00
—
—
—
1.7e+00
1.1e+00
cases:8.27%
controls:3.68%
cases:8.27%
controls:2.41%
—
—
—
—
—
—
cases:11.63%
controls:2.24%
cases:18.18%
controls:7.18%
11
49
122
1281
11
32
122
1298
—
—
—
15
29
114
1266
18
74
81
956
Immunization
WW200 [2001310599]
2.8e+00
—
—
—
—
1.0e+50
—
cases:9.02%
controls:0.60%
—
—
—
—
—
—
—
—
cases:7.75%
controls:0.00%
—
—
12
8
121
1322
—
—
—
—
10
0
119
1295
—
pH of Urine
2756-5 [3015736]
4.8e-01
1.1e+00
—
—
—
1.5e+00
7.6e-01
cases:12.03%
controls:7.82%
cases:10.53%
controls:3.76%
—
—
—
—
—
—
cases:13.18%
controls:3.32%
cases:22.22%
controls:11.75%
16
104
117
1226
14
50
119
1280
—
—
—
17
43
112
1252
22
121
77
909
Vomiting
D10 [2002000309]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:0.49%
—
—
—
—
—
—
6
5
93
1025
Need for immunization against influenza
Z25.1 [45581017]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.12%
controls:1.07%
—
—
—
—
—
—
12
11
87
1019
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.9e-01
2.2e-01
1.6e+00
—
2.5e+00
5.7e-01
4.0e-01
cases:21.05%
controls:15.34%
cases:10.53%
controls:8.65%
cases:3.76%
controls:0.75%
—
—
cases:6.06%
controls:0.53%
cases:13.18%
controls:7.88%
cases:29.29%
controls:21.75%
28
204
105
1126
14
115
119
1215
5
10
128
1320
—
8
7
124
1323
17
102
112
1193
29
224
70
806
Hospital outpatient
ZY010 [2001311599]
—
-1.0e+50
—
—
—
—
2.4e+00
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:5.05%
controls:0.49%
—
0
7
133
1323
—
—
—
—
5
5
94
1025
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
-2.5e-01
—
—
—
2.3e+00
2.9e-01
8.3e-02
cases:6.02%
controls:7.59%
—
—
—
—
—
—
cases:3.79%
controls:0.38%
cases:3.88%
controls:2.93%
cases:12.12%
controls:11.26%
8
101
125
1229
—
—
—
5
5
127
1325
5
38
124
1257
12
116
87
914
Lumbar puncture
TAB00 [2001300538]
2.3e+00
—
—
—
—
—
—
cases:4.51%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
127
1324
—
—
—
—
—
—
Antenatal screening for malformation
717800004 [36713462]
-1.0e+50
-1.0e+50
—
—
—
2.3e+00
—
cases:0.00%
controls:1.80%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:3.88%
controls:0.39%
—
—
0
24
133
1306
0
8
133
1322
—
—
—
5
5
124
1290
—
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:0.68%
—
—
—
—
—
—
6
7
93
1023
Dermatitis, unspecified
L30.9 [45572271]
1.3e+00
2.1e+00
—
—
—
—
1.0e+00
cases:6.77%
controls:2.03%
cases:6.02%
controls:0.75%
—
—
—
—
—
—
—
—
cases:8.08%
controls:3.01%
9
27
124
1303
8
10
125
1320
—
—
—
—
8
31
91
999
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:0.78%
—
—
—
—
—
—
6
8
93
1022
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
6.8e-01
—
—
—
—
2.1e+00
1.2e+00
cases:6.77%
controls:3.53%
—
—
—
—
—
—
—
—
cases:4.65%
controls:0.62%
cases:11.11%
controls:3.69%
9
47
124
1283
—
—
—
—
6
8
123
1287
11
38
88
992
Pain in throat
R07.0 [45592406]
2.1e+00
—
—
—
—
—
—
cases:4.51%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
127
1322
—
—
—
—
—
—
Diarrhoea
D11 [2002000310]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.12%
controls:1.75%
—
—
—
—
—
—
12
18
87
1012
Platelets [#/volume] in Blood
26515-7 [3007461]
2.2e-01
5.7e-01
1.3e+00
—
7.4e-01
7.2e-01
3.7e-01
cases:42.11%
controls:36.77%
cases:39.85%
controls:27.29%
cases:18.80%
controls:5.86%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.10%
cases:64.65%
controls:55.92%
56
489
77
841
53
363
80
967
25
78
108
1252
—
15
77
117
1253
56
351
73
944
64
576
35
454
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.9e-01
4.8e-01
1.2e+00
—
7.3e-01
8.4e-01
5.8e-01
cases:38.35%
controls:31.80%
cases:31.58%
controls:22.18%
cases:12.03%
controls:3.98%
—
—
cases:9.09%
controls:4.59%
cases:38.76%
controls:21.47%
cases:62.63%
controls:48.35%
51
423
82
907
42
295
91
1035
16
53
117
1277
—
12
61
120
1269
50
278
79
1017
62
498
37
532
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.1e-01
5.8e-01
1.3e+00
—
7.4e-01
7.3e-01
4.1e-01
cases:42.11%
controls:37.07%
cases:40.60%
controls:27.59%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.03%
cases:65.66%
controls:55.92%
56
493
77
837
54
367
79
963
25
79
108
1251
—
15
77
117
1253
56
350
73
945
65
576
34
454
MCH [Entitic mass]
28539-5 [3035941]
2.2e-01
5.9e-01
1.3e+00
—
7.4e-01
7.2e-01
4.1e-01
cases:42.11%
controls:36.92%
cases:40.60%
controls:27.52%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.10%
cases:65.66%
controls:56.02%
56
491
77
839
54
366
79
964
25
79
108
1251
—
15
77
117
1253
56
351
73
944
65
577
34
453
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.1e-01
5.8e-01
1.3e+00
—
7.4e-01
7.2e-01
4.1e-01
cases:42.11%
controls:37.07%
cases:40.60%
controls:27.59%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.18%
cases:65.66%
controls:56.02%
56
493
77
837
54
367
79
963
25
79
108
1251
—
15
77
117
1253
56
352
73
943
65
577
34
453
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.0e-01
5.8e-01
1.3e+00
—
7.4e-01
7.2e-01
4.1e-01
cases:42.11%
controls:37.29%
cases:40.60%
controls:27.67%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.18%
cases:65.66%
controls:56.02%
56
496
77
834
54
368
79
962
25
79
108
1251
—
15
77
117
1253
56
352
73
943
65
577
34
453
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.1e-01
5.8e-01
1.3e+00
—
7.4e-01
7.2e-01
4.0e-01
cases:42.11%
controls:37.07%
cases:40.60%
controls:27.74%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.26%
cases:65.66%
controls:56.12%
56
493
77
837
54
369
79
961
25
79
108
1251
—
15
77
117
1253
56
353
73
942
65
578
34
452
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.1e-01
5.8e-01
1.3e+00
—
7.4e-01
7.2e-01
4.1e-01
cases:42.11%
controls:37.07%
cases:40.60%
controls:27.67%
cases:18.80%
controls:5.94%
—
—
cases:11.36%
controls:5.79%
cases:43.41%
controls:27.26%
cases:65.66%
controls:56.02%
56
493
77
837
54
368
79
962
25
79
108
1251
—
15
77
117
1253
56
353
73
942
65
577
34
453
doxycycline; oral, parenteral
J01AA02 [21602800]
4.1e-01
5.8e-01
—
—
—
1.1e+00
8.5e-01
cases:22.56%
controls:16.24%
cases:9.02%
controls:5.26%
—
—
—
—
—
—
cases:12.40%
controls:4.32%
cases:27.27%
controls:13.79%
30
216
103
1114
12
70
121
1260
—
—
—
16
56
113
1239
27
142
72
888
Abdominal pain/cramps general
D01 [2002000300]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:1.07%
—
—
—
—
—
—
7
11
92
1019
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.8e+00
—
—
—
—
1.6e+00
9.1e-01
cases:15.79%
controls:3.08%
—
—
—
—
—
—
—
—
cases:6.20%
controls:1.31%
cases:13.13%
controls:5.73%
21
41
112
1289
—
—
—
—
8
17
121
1278
13
59
86
971
Right side
ZXA00 [2001311346]
7.9e-01
—
—
—
—
-1.0e+50
1.7e+00
cases:4.51%
controls:2.11%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:9.09%
controls:1.84%
6
28
127
1302
—
—
—
—
0
5
129
1290
9
19
90
1011
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
6.9e-01
5.6e-01
—
—
—
9.9e-01
1.6e+00
cases:10.53%
controls:5.56%
cases:3.76%
controls:2.18%
—
—
—
—
—
—
cases:4.65%
controls:1.78%
cases:19.19%
controls:4.56%
14
74
119
1256
5
29
128
1301
—
—
—
6
23
123
1272
19
47
80
983
Bacteria [Presence] in Urine
87829-8 [36304419]
8.3e-01
8.6e-01
—
—
—
1.1e+00
1.6e+00
cases:12.03%
controls:5.64%
cases:4.51%
controls:1.95%
—
—
—
—
—
—
cases:4.65%
controls:1.62%
cases:20.20%
controls:4.95%
16
75
117
1255
6
26
127
1304
—
—
—
6
21
123
1274
20
51
79
979
Deposits [accretions] on teeth betel
K03.65 [2000502690]
1.1e+00
1.5e+00
—
—
—
—
1.6e+00
cases:8.27%
controls:2.78%
cases:3.76%
controls:0.90%
—
—
—
—
—
—
—
—
cases:13.13%
controls:3.01%
11
37
122
1293
5
12
128
1318
—
—
—
—
13
31
86
999
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
9.9e-01
—
—
—
—
1.4e+00
1.6e+00
cases:6.77%
controls:2.63%
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.00%
cases:12.12%
controls:2.82%
9
35
124
1295
—
—
—
—
5
13
124
1282
12
29
87
1001
azithromycin; oral, parenteral
J01FA10 [21602978]
7.9e-01
1.6e+00
—
—
—
6.8e-01
9.7e-01
cases:16.54%
controls:8.27%
cases:6.77%
controls:1.50%
—
—
—
—
—
—
cases:3.88%
controls:2.01%
cases:12.12%
controls:4.95%
22
110
111
1220
9
20
124
1310
—
—
—
5
26
124
1269
12
51
87
979
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
4.9e-01
8.0e-01
1.2e+00
—
—
7.1e-01
7.5e-01
cases:30.83%
controls:21.50%
cases:21.80%
controls:11.13%
cases:6.02%
controls:1.80%
—
—
—
—
cases:20.93%
controls:11.51%
cases:52.53%
controls:34.27%
41
286
92
1044
29
148
104
1182
8
24
125
1306
—
—
27
149
102
1146
52
353
47
677
Throat symptom/complaint
R21 [2002000891]
5.6e-01
1.5e+00
—
—
—
—
1.5e+00
cases:6.02%
controls:3.53%
cases:3.76%
controls:0.90%
—
—
—
—
—
—
—
—
cases:11.11%
controls:2.72%
8
47
125
1283
5
12
128
1318
—
—
—
—
11
28
88
1002
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.5e+00
—
—
—
—
—
3.4e-01
cases:7.52%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:4.37%
10
24
123
1306
—
—
—
—
—
6
45
93
985
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.8e-01
5.9e-01
—
—
—
7.9e-01
1.5e+00
cases:12.03%
controls:6.47%
cases:4.51%
controls:2.56%
—
—
—
—
—
—
cases:4.65%
controls:2.16%
cases:20.20%
controls:5.53%
16
86
117
1244
6
34
127
1296
—
—
—
6
28
123
1267
20
57
79
973
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
1.1e+00
—
—
—
—
—
1.4e+00
cases:6.77%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
cases:13.13%
controls:3.50%
9
32
124
1298
—
—
—
—
—
13
36
86
994
Issue of repeat prescription
Z76.0 [45542456]
1.3e+00
1.3e+00
—
—
—
1.4e+00
9.7e-01
cases:6.02%
controls:1.73%
cases:4.51%
controls:1.28%
—
—
—
—
—
—
cases:8.53%
controls:2.24%
cases:12.12%
controls:4.95%
8
23
125
1307
6
17
127
1313
—
—
—
11
29
118
1266
12
51
87
979
Gingivitis (chronic) NOS
K05.10 [2000502717]
1.4e+00
—
—
—
—
—
7.3e-01
cases:8.27%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:3.01%
11
29
122
1301
—
—
—
—
—
6
31
93
999
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
9.0e-01
—
—
—
—
1.2e+00
1.4e+00
cases:6.77%
controls:2.86%
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.24%
cases:11.11%
controls:3.01%
9
38
124
1292
—
—
—
—
5
16
124
1279
11
31
88
999
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.3e-01
1.3e+00
—
—
—
9.5e-01
1.4e+00
cases:8.27%
controls:5.04%
cases:7.52%
controls:2.26%
—
—
—
—
—
—
cases:4.65%
controls:1.85%
cases:17.17%
controls:4.95%
11
67
122
1263
10
30
123
1300
—
—
—
6
24
123
1271
17
51
82
979
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
4.1e-01
—
—
—
—
—
1.4e+00
cases:6.77%
controls:4.59%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:3.11%
9
61
124
1269
—
—
—
—
—
11
32
88
998
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
4.9e-01
9.6e-01
1.9e+00
—
2.0e+00
1.3e+00
6.2e-01
cases:13.53%
controls:8.72%
cases:11.28%
controls:4.66%
cases:3.76%
controls:0.60%
—
—
cases:3.79%
controls:0.53%
cases:14.73%
controls:4.32%
cases:24.24%
controls:14.66%
18
116
115
1214
15
62
118
1268
5
8
128
1322
—
5
7
127
1323
19
56
110
1239
24
151
75
879
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.7e-01
9.2e-01
1.9e+00
—
2.0e+00
1.3e+00
6.2e-01
cases:13.53%
controls:8.87%
cases:11.28%
controls:4.81%
cases:3.76%
controls:0.60%
—
—
cases:3.79%
controls:0.53%
cases:14.73%
controls:4.32%
cases:24.24%
controls:14.66%
18
118
115
1212
15
64
118
1266
5
8
128
1322
—
5
7
127
1323
19
56
110
1239
24
151
75
879
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
4.7e-01
9.4e-01
2.0e+00
—
2.0e+00
1.3e+00
6.3e-01
cases:13.53%
controls:8.87%
cases:11.28%
controls:4.74%
cases:3.76%
controls:0.53%
—
—
cases:3.79%
controls:0.53%
cases:14.73%
controls:4.32%
cases:24.24%
controls:14.56%
18
118
115
1212
15
63
118
1267
5
7
128
1323
—
5
7
127
1323
19
56
110
1239
24
150
75
880
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.3e-01
3.0e-01
7.5e-01
—
1.3e+00
6.9e-01
5.6e-01
cases:34.59%
controls:27.44%
cases:21.80%
controls:17.07%
cases:6.02%
controls:2.93%
—
—
cases:9.85%
controls:2.93%
cases:27.91%
controls:16.22%
cases:53.54%
controls:39.81%
46
365
87
965
29
227
104
1103
8
39
125
1291
—
13
39
119
1291
36
210
93
1085
53
410
46
620
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
8.2e-01
6.7e-01
—
—
—
1.0e+00
1.2e+00
cases:6.77%
controls:3.08%
cases:3.76%
controls:1.95%
—
—
—
—
—
—
cases:4.65%
controls:1.70%
cases:13.13%
controls:4.27%
9
41
124
1289
5
26
128
1304
—
—
—
6
22
123
1273
13
44
86
986
zopiclone; oral
N05CF01 [21604654]
7.2e-01
9.9e-01
—
—
—
5.3e-01
1.2e+00
cases:9.02%
controls:4.59%
cases:5.26%
controls:2.03%
—
—
—
—
—
—
cases:3.88%
controls:2.32%
cases:15.15%
controls:5.05%
12
61
121
1269
7
27
126
1303
—
—
—
5
30
124
1265
15
52
84
978
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
6.5e-01
1.1e+00
—
—
—
—
1.2e+00
cases:8.27%
controls:4.51%
cases:4.51%
controls:1.58%
—
—
—
—
—
—
—
—
cases:16.16%
controls:5.53%
11
60
122
1270
6
21
127
1309
—
—
—
—
16
57
83
973
Health maint/preventive medicine
A98 [2002000231]
3.1e-01
2.0e-01
1.2e+00
—
5.3e-01
5.4e-01
5.3e-01
cases:44.36%
controls:36.99%
cases:27.07%
controls:23.23%
cases:9.77%
controls:3.23%
—
—
cases:6.82%
controls:4.14%
cases:34.88%
controls:23.86%
cases:61.62%
controls:48.64%
59
492
74
838
36
309
97
1021
13
43
120
1287
—
9
55
123
1275
45
309
84
986
61
501
38
529
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.0e-01
7.0e-01
—
—
—
6.2e-01
1.2e+00
cases:12.03%
controls:6.99%
cases:6.02%
controls:3.08%
—
—
—
—
—
—
cases:4.65%
controls:2.55%
cases:19.19%
controls:6.99%
16
93
117
1237
8
41
125
1289
—
—
—
6
33
123
1262
19
72
80
958
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
4.6e-01
8.0e-01
—
—
—
9.1e-01
1.1e+00
cases:16.54%
controls:11.13%
cases:9.77%
controls:4.66%
—
—
—
—
—
—
cases:12.40%
controls:5.41%
cases:36.36%
controls:16.50%
22
148
111
1182
13
62
120
1268
—
—
—
16
70
113
1225
36
170
63
860
Upper gastrointestinal surgery
106 [44777669]
5.6e-01
2.8e-01
—
—
—
9.3e-01
1.1e+00
cases:12.03%
controls:7.22%
cases:4.51%
controls:3.46%
—
—
—
—
—
—
cases:6.20%
controls:2.55%
cases:19.19%
controls:7.67%
16
96
117
1234
6
46
127
1284
—
—
—
8
33
121
1262
19
79
80
951
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
8.7e-01
6.0e-01
—
—
—
1.2e+00
9.7e-01
cases:15.04%
controls:6.92%
cases:8.27%
controls:4.74%
—
—
—
—
—
—
cases:8.53%
controls:2.78%
cases:21.21%
controls:9.22%
20
92
113
1238
11
63
122
1267
—
—
—
11
36
118
1259
21
95
78
935
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4.3e-01
6.4e-01
1.3e+00
—
—
7.3e-01
9.2e-01
cases:29.32%
controls:21.20%
cases:21.80%
controls:12.86%
cases:6.77%
controls:1.88%
—
—
—
—
cases:23.26%
controls:12.74%
cases:56.57%
controls:34.08%
39
282
94
1048
29
171
104
1159
9
25
124
1305
—
—
30
165
99
1130
56
351
43
679
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.1e-01
1.0e+00
—
—
—
8.9e-01
8.9e-01
cases:16.54%
controls:11.58%
cases:10.53%
controls:4.06%
—
—
—
—
—
—
cases:12.40%
controls:5.48%
cases:28.28%
controls:13.98%
22
154
111
1176
14
54
119
1276
—
—
—
16
71
113
1224
28
144
71
886
Simple examination of mouth
SAA01 [2001310274]
2.9e-01
5.1e-01
—
—
—
5.6e-01
8.0e-01
cases:28.57%
controls:23.08%
cases:15.79%
controls:10.08%
—
—
—
—
—
—
cases:17.05%
controls:10.50%
cases:48.48%
controls:29.71%
38
307
95
1023
21
134
112
1196
—
—
—
22
136
107
1159
48
306
51
724
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
nortriptyline; oral, parenteral
N06AA10 [21604697]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.17%
0
17
133
1313
0
6
133
1324
—
—
—
—
0
12
99
1018
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
8
99
1022
Fluoride application or other respective small prophylactic procedure
SCC01 [2001310310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
133
1321
—
—
—
—
—
—
Syphilis, unspecified
A53.9 [45600422]
—
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:75.19%
controls:0.00%
cases:32.58%
controls:0.00%
cases:20.93%
controls:0.00%
cases:14.14%
controls:0.00%
—
—
—
100
0
33
1330
43
0
89
1330
27
0
102
1295
14
0
85
1030
cetirizine; oral
R06AE07 [21603497]
1.0e-01
9.3e-01
-1.0e+50
—
—
5.4e-01
6.2e-01
cases:7.52%
controls:6.84%
cases:6.77%
controls:2.78%
cases:0.00%
controls:0.38%
—
—
—
—
cases:5.43%
controls:3.24%
cases:11.11%
controls:6.31%
10
91
123
1239
9
37
124
1293
0
5
133
1325
—
—
7
42
122
1253
11
65
88
965
Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
32166-1 [3008714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
133
1322
—
—
—
—
—
—
diclofenac
S01BC03 [21603641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
99
1024
Urinary tract ultrasound examination
KH1AE [2001306329]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Malignant neoplasm prostate
Y77 [2002001445]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
Contusion of knee
S80.0 [45569633]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
16
99
1014
Ocular pain
H57.1 [45596140]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
99
1024
Combined vitrectomy and retinal procedure
CKD92 [2001301424]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Primary gonarthrosis, bilateral
M17.0 [45562648]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
0
5
133
1325
—
—
—
0
8
129
1287
—
Other angina pectoris stenosed coronary artery
I20.81 [2000502397]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
7
99
1023
Root filling of tooth with onetwo root canals
SGB20 [2001310389]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
Pure hypercholesterolaemia
E78.0 [45542771]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.70%
—
—
—
—
—
—
—
0
22
129
1273
—
Other benign neoplasms of skin
D23 [45590988]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Supervision of other normal pregnancy
Z34.8 [45537628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
133
1318
—
—
—
—
—
—
Social worker
Z2446 [2001311559]
1.6e+00
—
—
—
—
—
2.2e+00
cases:4.51%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:0.58%
6
12
127
1318
—
—
—
—
—
5
6
94
1024
Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess
A54.0 [45547416]
1.0e+50
—
—
—
—
—
—
cases:5.26%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
7
0
126
1330
—
—
—
—
—
—
Headache
N01 [2002000720]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
6.4e-02
8.4e-01
—
—
—
—
8.8e-01
cases:3.76%
controls:3.53%
cases:3.76%
controls:1.65%
—
—
—
—
—
—
—
—
cases:12.12%
controls:5.44%
5
47
128
1283
5
22
128
1308
—
—
—
—
12
56
87
974
Neck symptom/complaint
L01 [2002000626]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:1.94%
—
—
—
—
—
—
6
20
93
1010
codeine and ibuprofen
N02AJ08 [1123631]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
losartan and diuretics
C09DA01 [21601834]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
Spirometry
127783003 [4133840]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
-2.1e-02
—
-1.0e+50
—
—
-1.0e+50
—
cases:3.76%
controls:3.83%
—
—
cases:0.00%
controls:0.38%
—
—
—
—
cases:0.00%
controls:0.54%
—
—
5
51
128
1279
—
0
5
133
1325
—
—
0
7
129
1288
—
Other complicated additional procedure necessary for restorative treatment
SFC92 [2001310370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Urination problems other
U05 [2002001140]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:0.97%
—
—
—
—
—
—
5
10
94
1020
ethylmorphine; oral
R05DA01 [21603397]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.08%
controls:2.52%
—
—
—
—
—
—
8
26
91
1004
Maternal care for excessive fetal growth
O36.6 [45543983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
candesartan; oral
C09CA06 [21601829]
1.1e-01
—
—
—
—
1.1e-01
3.2e-01
cases:3.76%
controls:3.38%
—
—
—
—
—
—
—
—
cases:3.88%
controls:3.47%
cases:8.08%
controls:6.02%
5
45
128
1285
—
—
—
—
5
45
124
1250
8
62
91
968
Zoster without complication
B02.9 [45581143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
7
99
1023
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
6
133
1324
—
—
—
0
6
129
1289
—
epinephrine
S01EA01 [21603673]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
6
129
1289
—
Outcome of delivery
Z37 [45581024]
-1.0e+50
-1.0e+50
—
—
—
1.9e+00
—
cases:0.00%
controls:2.93%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:3.88%
controls:0.62%
—
—
0
39
133
1291
0
6
133
1324
—
—
—
5
8
124
1287
—
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
0
12
133
1318
—
—
—
0
10
129
1285
—
Senile nuclear cataract
H25.1 [45581628]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
ciclesonide; nasal
R01AD13 [43534836]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
0
9
133
1321
—
—
—
0
9
129
1286
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
7
99
1023
Operation for osteochondritis of knee, arthroscopic
NGF25 [2001308133]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
7
133
1323
—
—
—
—
—
0
5
99
1025
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
8
99
1022
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
9.5e-01
—
—
—
—
9.9e-01
6.4e-01
cases:10.53%
controls:4.36%
—
—
—
—
—
—
—
—
cases:6.20%
controls:2.39%
cases:16.16%
controls:9.22%
14
58
119
1272
—
—
—
—
8
31
121
1264
16
95
83
935
Supraglottic ventilation device
WX702 [2001310818]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
133
1322
—
—
—
—
—
—
Lateral epicondylitis
M77.1 [45572551]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
25373-2 [3019145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
insulin lispro; parenteral
A10AD04 [21600732]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
Detailed ultrasound examination of fetus including color doppler method
MA2DE [2001306835]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
133
1322
—
—
—
—
—
—
Hyperlipidaemia, unspecified
E78.5 [45537986]
1.6e+00
—
—
—
—
—
—
cases:3.76%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
128
1320
—
—
—
—
—
—
Recurrent depression, mild episode without somatic syndrome
F33.00 [2000501982]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
7
99
1023
General Practice
1 [38004446]
1.9e-01
2.5e-01
—
—
—
6.5e-01
7.1e-01
cases:12.03%
controls:10.15%
cases:4.51%
controls:3.53%
—
—
—
—
—
—
cases:6.98%
controls:3.78%
cases:20.20%
controls:11.07%
16
135
117
1195
6
47
127
1283
—
—
—
9
49
120
1246
20
114
79
916
Chronic gingivitis
K05.18 [2000502721]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
Neuropsychological investigation
XA800 [2001300412]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
11
99
1019
drospirenone and ethinylestradiol
G03AA12 [21602485]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.35%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
18
133
1312
0
8
133
1322
—
—
—
0
8
129
1287
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
1.5e+00
—
—
—
—
-1.0e+50
—
cases:3.76%
controls:0.90%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
5
12
128
1318
—
—
—
—
0
6
129
1289
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
133
1323
—
0
8
132
1322
—
—
Post-traumatic stress disorder
F43.1 [45595909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
9
99
1021
Supraventricular tachycardia
I47.1 [45567178]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.78%
0
7
133
1323
—
—
—
—
0
5
129
1290
0
8
99
1022
fluocortolone
D07AC05 [21602124]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
11
99
1019
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
2.8e-01
8.2e-01
—
—
—
7.0e-01
5.6e-01
cases:9.77%
controls:7.59%
cases:4.51%
controls:2.03%
—
—
—
—
—
—
cases:5.43%
controls:2.78%
cases:13.13%
controls:7.96%
13
101
120
1229
6
27
127
1303
—
—
—
7
36
122
1259
13
82
86
948
hydrocortisone and antiinfectives
S01CA03 [21603654]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
Dizziness and giddiness
R42 [45568132]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.23%
—
0
7
133
1323
—
—
—
—
0
23
99
1007
Caries limited to enamel
K02.0 [45576967]
—
—
—
—
—
-1.0e+50
3.0e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
cases:5.05%
controls:3.79%
—
—
—
—
—
0
12
129
1283
5
39
94
991
Ulcerative colitis
K51 [45557655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
allopurinol; oral, parenteral
M04AA01 [21604131]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.35%
cases:0.00%
controls:1.20%
—
—
—
—
—
—
cases:0.00%
controls:1.16%
cases:0.00%
controls:1.84%
0
18
133
1312
0
16
133
1314
—
—
—
0
15
129
1280
0
19
99
1011
Occupational health examination
Z10.0 [45581006]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
8
133
1322
—
—
—
—
—
Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
9
99
1021
Uncompl labour/delivery livebirth
W90 [2002001277]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Chest symptom/complaint
L04 [2002000629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
133
1319
—
—
—
—
—
—
insulin detemir; parenteral
A10AE05 [21600740]
—
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:4.08%
—
—
0
9
133
1321
—
—
—
0
42
99
988
pH of Blood
11558-4 [3010421]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
1.2e+00
—
—
—
—
—
1.5e+00
cases:3.76%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:1.65%
5
15
128
1315
—
—
—
—
—
7
17
92
1013
Osmolality of Urine
2695-5 [3026782]
4.3e-01
1.2e+00
—
—
—
—
1.2e+00
cases:6.02%
controls:3.98%
cases:3.76%
controls:1.13%
—
—
—
—
—
—
—
—
cases:11.11%
controls:3.50%
8
53
125
1277
5
15
128
1315
—
—
—
—
11
36
88
994
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
11
99
1019
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
0
13
133
1317
—
—
—
0
11
129
1284
—
Other specified pulpit
K04.08 [2000502703]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
0
8
133
1322
—
—
—
0
7
129
1288
—
Chlamydophila sp Ab [Presence] in Serum
46179-8 [3047007]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
11
133
1319
0
8
133
1322
—
—
—
0
8
129
1287
—
Orthopedic Surgery
20 [38004465]
-2.1e-01
—
-1.0e+50
—
—
—
1.6e-01
cases:9.77%
controls:11.80%
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:15.15%
controls:13.20%
13
157
120
1173
—
0
11
133
1319
—
—
—
15
136
84
894
tizanidine; oral
M03BX02 [21604116]
3.2e-01
-1.0e-01
—
—
-1.0e+50
1.6e-01
2.2e-01
cases:18.80%
controls:14.44%
cases:4.51%
controls:4.96%
—
—
—
—
cases:0.00%
controls:0.83%
cases:6.20%
controls:5.33%
cases:17.17%
controls:14.27%
25
192
108
1138
6
66
127
1264
—
—
0
11
132
1319
8
69
121
1226
17
147
82
883
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
—
—
—
—
—
3.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:4.37%
—
—
—
—
—
—
6
45
93
985
Breathing problem other
R04 [2002000885]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Examination for driving licence
Z02.4 [45552056]
7.9e-01
—
—
—
—
—
—
cases:4.51%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
6
28
127
1302
—
—
—
—
—
—
tadalafil; oral
G04BE08 [21602653]
1.5e+00
1.4e+00
—
—
—
1.1e+00
8.9e-01
cases:3.76%
controls:0.90%
cases:4.51%
controls:1.13%
—
—
—
—
—
—
cases:3.88%
controls:1.31%
cases:5.05%
controls:2.14%
5
12
128
1318
6
15
127
1315
—
—
—
5
17
124
1278
5
22
94
1008
Neurology
13 [38004458]
3.3e-01
—
-1.0e+50
—
—
7.1e-01
7.0e-01
cases:11.28%
controls:8.35%
—
—
cases:0.00%
controls:0.68%
—
—
—
—
cases:6.98%
controls:3.55%
cases:16.16%
controls:8.74%
15
111
118
1219
—
0
9
133
1321
—
—
9
46
120
1249
16
90
83
940
Balloon angioplasty and metallic stent
AN3 [2000200165]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
133
1318
—
—
—
—
—
—
Influenza virus A+B Ag [Presence] in Specimen
24015-0 [3024891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
Contraception intrauterine
W12 [2002001212]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
0
15
133
1315
—
—
—
0
12
129
1283
—
clozapine; oral, parenteral
N05AH02 [21604542]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.38%
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
6
133
1324
0
6
133
1324
0
5
133
1325
—
—
0
7
129
1288
—
Hearing complaint
H02 [2002000476]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
0
9
133
1321
—
—
—
0
5
129
1290
—
tamsulosin; oral
G04CA02 [21602669]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
0
5
132
1325
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.17%
—
—
—
—
—
—
5
12
94
1018
dabigatran etexilate; oral
B01AE07 [21601026]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
—
Horse dander IgE Ab [Units/volume] in Serum
6143-2 [3010726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
10
99
1020
chloramphenicol
S01AA01 [21603554]
3.1e-01
6.5e-01
-1.0e+50
—
—
9.9e-01
3.6e-01
cases:9.77%
controls:7.37%
cases:6.02%
controls:3.23%
cases:0.00%
controls:0.38%
—
—
—
—
cases:6.98%
controls:2.70%
cases:16.16%
controls:11.84%
13
98
120
1232
8
43
125
1287
0
5
133
1325
—
—
9
35
120
1260
16
122
83
908
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
oxycodone and naloxone; oral
N02AA55 [21604265]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
19
133
1311
—
—
—
—
0
8
129
1287
—
One-surface restoration
SFA10 [2001310358]
3.7e-01
—
-1.0e+50
—
—
—
-4.7e-03
cases:18.80%
controls:13.76%
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:18.18%
controls:18.25%
25
183
108
1147
—
0
9
133
1321
—
—
—
18
188
81
842
Occupational therapy functional assessment compilation tool
440362002 [4234641]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:3.79%
—
—
—
—
—
—
9
39
90
991
Place of Employment-Worksite
18 [581475]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
5
133
1325
—
—
—
—
—
0
6
99
1024
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
-3.6e-02
2.9e-01
—
—
—
-1.3e-01
1.7e-01
cases:17.29%
controls:17.82%
cases:12.03%
controls:9.25%
—
—
—
—
—
—
cases:6.98%
controls:7.88%
cases:29.29%
controls:25.83%
23
237
110
1093
16
123
117
1207
—
—
—
9
102
120
1193
29
266
70
764
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
8
129
1287
—
Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
0
10
133
1320
—
—
—
—
—
0
11
99
1019
warfarin; oral, parenteral
B01AA03 [21600965]
—
—
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.60%
—
—
cases:0.00%
controls:0.75%
—
—
cases:0.00%
controls:3.11%
—
—
0
8
133
1322
—
0
10
132
1320
—
0
32
99
998
methylphenidate; oral
N06BA04 [21604757]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
0
9
133
1321
0
5
133
1325
—
—
—
—
Mitral (valve) prolapse
I34.1 [45552788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
0
5
132
1325
—
—
Administration of medicine
SPAT1254 [2001700355]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
Impingement syndrome of shoulder
M75.4 [45553266]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
11
133
1319
—
—
—
—
—
0
6
99
1024
Bacteria identified in Stool by Culture
625-4 [3025941]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
0
11
133
1319
—
—
0
6
132
1324
—
—
Participation in compiling a psychiatric treatment plan
ICZ03 [2001304119]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
0
8
133
1322
—
—
—
0
5
129
1290
—
indometacin
C01EB03 [21600365]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
0
9
129
1286
—
chloramphenicol
S03AA08 [21605197]
3.1e-01
6.5e-01
-1.0e+50
—
—
9.9e-01
3.6e-01
cases:9.77%
controls:7.37%
cases:6.02%
controls:3.23%
cases:0.00%
controls:0.38%
—
—
—
—
cases:6.98%
controls:2.70%
cases:16.16%
controls:11.84%
13
98
120
1232
8
43
125
1287
0
5
133
1325
—
—
9
35
120
1260
16
122
83
908
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
—
—
—
—
—
4.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:3.30%
—
—
—
—
—
—
5
34
94
996
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
CT angiography of head and neck vasculature
PA7AD [2001300233]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Thrombin time
3243-3 [3036489]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
sodium fluoride; oral
A01AA01 [21600005]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
11
133
1319
—
—
—
—
0
6
129
1289
—
Opening and preparing the root canals
SGA02 [2001310380]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
8
129
1287
—
Retention of urine
R33 [45587507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
99
1024
Counselling, unspecified
Z71.9 [45561648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
133
1321
—
—
—
—
—
—
Office Visit
OMOP4822458 [581477]
-6.3e-02
—
—
—
—
1.5e+00
6.9e-01
cases:7.52%
controls:7.97%
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.85%
cases:10.10%
controls:5.34%
10
106
123
1224
—
—
—
—
5
11
124
1284
10
55
89
975
Diabetes, non-insulin-treated
215 [2001600211]
5.9e-01
—
—
—
—
—
—
cases:4.51%
controls:2.56%
—
—
—
—
—
—
—
—
—
—
—
—
6
34
127
1296
—
—
—
—
—
—
Gastroenteritis presumed infection
D73 [2002000371]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
10
99
1020
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
-4.3e-01
7.2e-01
—
—
-1.0e+50
8.3e-01
7.2e-01
cases:5.26%
controls:7.89%
cases:6.02%
controls:3.01%
—
—
—
—
cases:0.00%
controls:0.38%
cases:4.65%
controls:2.08%
cases:17.17%
controls:9.13%
7
105
126
1225
8
40
125
1290
—
—
0
5
132
1325
6
27
123
1268
17
94
82
936
Other obesity
E66.8 [45533036]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
Monitoring the use of the aid
R5140 [2001310249]
7.5e-01
—
—
—
—
—
—
cases:3.76%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
128
1306
—
—
—
—
—
—
Gastro-oesophageal reflux disease
K21 [45586708]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
8
133
1322
0
6
133
1324
—
—
—
—
—
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
—
Plastic repair of ligament of knee not using prosthetic material, anterior cruciate, arthroscopic
NGE35 [2001308121]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
2.4e-01
-9.9e-02
—
—
-1.0e+50
5.6e-01
-1.8e-01
cases:6.02%
controls:4.81%
cases:3.76%
controls:4.14%
—
—
—
—
cases:0.00%
controls:0.53%
cases:6.20%
controls:3.63%
cases:8.08%
controls:9.51%
8
64
125
1266
5
55
128
1275
—
—
0
7
132
1323
8
47
121
1248
8
98
91
932
Split tooth for reasons other than trauma
K03.82 [2000502700]
—
-1.0e+50
—
—
—
—
2.0e-01
—
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
cases:5.05%
controls:4.17%
—
0
19
133
1311
—
—
—
—
5
43
94
987
calcium (different salts in combination); oral
A12AA20 [21600872]
3.6e-01
—
—
—
—
—
—
cases:6.02%
controls:4.29%
—
—
—
—
—
—
—
—
—
—
—
—
8
57
125
1273
—
—
—
—
—
—
Outlet vacuum delivery
MAE00 [2001306882]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
—
Injury of conjunctiva and corneal abrasion without mention of foreign body
S05.0 [45544236]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
7
99
1023
Secondary syphilis of skin and mucous membranes
A51.3 [45537730]
1.0e+50
—
—
—
1.0e+50
1.0e+50
—
cases:3.76%
controls:0.00%
—
—
—
—
—
—
cases:6.06%
controls:0.00%
cases:3.88%
controls:0.00%
—
—
5
0
128
1330
—
—
—
8
0
124
1330
5
0
124
1295
—
Opiates [Presence] in Urine
3879-4 [3027008]
7.5e-01
—
—
—
—
—
1.1e+00
cases:4.51%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.75%
6
29
127
1301
—
—
—
—
—
5
18
94
1012
Primary coxarthrosis, bilateral
M16.0 [45543482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Supervision of other high-risk pregnancies
Z35.8 [45552076]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
7
133
1323
—
—
—
—
—
0
7
99
1023
12 lead EKG panel
34534-8 [3044889]
3.2e-01
-2.5e-01
—
—
-1.0e+50
2.0e-01
3.3e-01
cases:18.05%
controls:13.76%
cases:6.02%
controls:7.59%
—
—
—
—
cases:0.00%
controls:0.98%
cases:6.98%
controls:5.79%
cases:28.28%
controls:22.14%
24
183
109
1147
8
101
125
1229
—
—
0
13
132
1317
9
75
120
1220
28
228
71
802
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
0
9
133
1321
—
—
—
—
—
Actinic keratosis
L57.0 [45591640]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
0
5
133
1325
—
—
—
—
—
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
0
5
133
1325
—
—
—
—
0
9
99
1021
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
6
133
1324
—
—
—
0
6
129
1289
—
Gout
M10 [45533711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
8
133
1322
—
—
—
—
—
0
6
99
1024
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
Hip X-ray examination
NF1AA [2001307894]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
0
6
133
1324
—
—
—
—
—
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
J07AH08 [21601303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
Periodontal treatment
SDA03 [2001310328]
3.0e-01
6.9e-01
—
—
-1.0e+50
7.3e-01
5.4e-01
cases:9.77%
controls:7.44%
cases:5.26%
controls:2.71%
—
—
—
—
cases:0.00%
controls:0.38%
cases:6.98%
controls:3.47%
cases:16.16%
controls:10.10%
13
99
120
1231
7
36
126
1294
—
—
0
5
132
1325
9
45
120
1250
16
104
83
926
Shoulder lesions
M75 [45557983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
—
Muscle strain
M62.6 [45587017]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Bacteria [#/volume] in Urine by Culture
100906-7 [1761482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
9
99
1021
bisoprolol and thiazides
C07BB07 [21601714]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
7
133
1323
0
6
133
1324
—
—
—
—
0
7
99
1023
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
—
-1.0e+50
—
—
—
—
2.2e+00
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:5.05%
controls:0.58%
—
0
7
133
1323
—
—
—
—
5
6
94
1024
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
Dental examination
Z01.2 [45581002]
6.2e-01
3.7e-01
—
—
—
1.2e+00
7.0e-01
cases:13.53%
controls:7.74%
cases:3.76%
controls:2.63%
—
—
—
—
—
—
cases:7.75%
controls:2.39%
cases:21.21%
controls:11.75%
18
103
115
1227
5
35
128
1295
—
—
—
10
31
119
1264
21
121
78
909
Viral intestinal infection, unspecified
A08.4 [45576230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
5
99
1025
Psychiatry
26 [38004469]
7.6e-01
3.8e-01
—
—
1.0e+00
8.7e-01
5.2e-01
cases:16.54%
controls:8.50%
cases:6.77%
controls:4.74%
—
—
—
—
cases:3.79%
controls:1.43%
cases:10.08%
controls:4.48%
cases:13.13%
controls:8.25%
22
113
111
1217
9
63
124
1267
—
—
5
19
127
1311
13
58
116
1237
13
85
86
945
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
hydroxocobalamin; parenteral
B03BA03 [21601123]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
6
129
1289
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
6.2e-02
—
-1.0e+50
—
—
—
—
cases:5.26%
controls:4.96%
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
7
66
126
1264
—
0
7
133
1323
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
8.6e-01
-1.0e+50
—
—
—
-1.0e+50
1.3e+00
cases:4.51%
controls:1.95%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:5.05%
controls:1.46%
6
26
127
1304
0
6
133
1324
—
—
—
0
8
129
1287
5
15
94
1015
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
-1.0e+50
—
—
—
-1.0e+50
5.8e-01
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
cases:7.07%
controls:4.08%
—
0
13
133
1317
—
—
—
0
12
129
1283
7
42
92
988
magnesium hydroxide; oral
G04BX01 [21602658]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
0
9
133
1321
—
—
—
—
—
0
8
99
1022
No procedures
SPAT1301 [2001700402]
—
—
-1.0e+50
—
—
—
-3.9e-02
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:5.05%
controls:5.24%
—
—
0
5
133
1325
—
—
—
5
54
94
976
Hematology
82 [38004501]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
0
12
133
1318
0
6
133
1324
—
—
—
0
9
129
1286
—
Ingrowing nail
L60.0 [45548199]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
8
133
1322
—
—
—
—
—
0
5
99
1025
Other specified cardiac arrhythmias
I49.8 [45576877]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
5
133
1325
—
—
—
—
—
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 [3010521]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
0
5
133
1325
—
—
—
—
0
5
99
1025
fluticasone furoate; nasal
R01AD12 [21605053]
-2.0e-01
3.3e-01
-1.0e+50
—
—
—
-1.2e-01
cases:7.52%
controls:9.02%
cases:5.26%
controls:3.83%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:8.08%
controls:9.03%
10
120
123
1210
7
51
126
1279
0
7
133
1323
—
—
—
8
93
91
937
Multiple inhalant allergen IgE Ab [Units/volume] in Serum
7492-2 [3002670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
133
1324
—
—
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
133
1317
—
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.50%
cases:0.00%
controls:0.38%
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
0
20
133
1310
0
5
133
1325
—
0
10
132
1320
—
—
Carpal tunnel syndrome
G56.0 [45566891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
133
1317
—
—
—
—
—
—
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
133
1323
—
—
—
—
—
—
Ventricular tachycardia
I47.2 [45586586]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
5
129
1290
—
Teeth/gum disease
D82 [2002000380]
-2.0e-01
—
—
—
—
—
2.4e-01
cases:6.02%
controls:7.22%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:8.16%
8
96
125
1234
—
—
—
—
—
10
84
89
946

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
104
34
98.97
173.54
11.1
2.0
11.25
—
titre
—
56
0
46
13
50.74
75.79
3.3
2.2
30.88
33.75
%
0.28
46
13
98
148
17.42
72.30
3.8
1.8
—
—
—
0
0
58
41
22.53
67.78
7.9
4.7
176.27
266.69
mg/l
0.48
52
26
89
208
9.14
42.10
6.3
1.7
—
—
—
0
0
64
142
7.15
30.41
5.5
1.7
—
—
—
0
0
90
421
3.87
14.85
5.8
3.4
24.87
195.54
e6/l
0.99
50
295
74
312
3.73
14.13
7.1
2.0
—
—
—
0
0
84
405
3.46
12.65
11.6
6.1
—
—
—
0
0
98
522
3.56
12.50
4.1
3.3
6.29
6.07
ph
0.80
33
323
75
351
3.29
11.62
10.1
6.1
—
—
—
0
0
57
242
3.20
10.16
2.4
1.7
—
—
—
0
0
89
489
3.04
10.00
5.7
4.8
38.13
36.68
g/l
1.56
89
470
48
189
3.27
9.64
3.6
2.4
1.76
1.68
e6/l
0.03
13
87
15
12
13.74
9.09
1.1
1.2
—
—
—
0
0
14
10
15.29
8.89
1.1
1.1
—
—
—
0
0
110
707
3.12
8.85
14.8
11.5
3.64
4.22
e9/l
1.97
96
623
17
19
9.94
8.81
1.1
1.1
—
—
—
0
0
103
642
2.96
8.71
4.3
3.5
0.00
0.00
estimate
—
8
136
102
634
2.93
8.64
4.2
3.4
0.00
0.00
estimate
—
8
136
22
55
4.52
8.41
1.0
1.4
268.60
273.35
miu/ml
—
5
35
103
649
2.90
8.40
4.3
3.5
0.00
0.00
estimate
—
6
125
19
31
6.86
7.85
1.3
1.2
—
—
—
0
0
101
652
2.70
7.48
13.8
7.4
0.19
0.19
e9/l
0.05
94
580
98
629
2.63
7.25
14.0
6.9
0.58
0.59
e9/l
0.32
90
551
18
31
6.45
7.18
1.2
1.1
—
—
—
0
0
98
633
2.60
7.10
14.0
6.9
0.04
0.04
e9/l
0.16
90
554
87
532
2.53
7.07
16.5
11.3
0.00
0.00
e9/l
0.50
75
436
16
25
7.03
6.85
1.1
1.1
11.11
3.76
e6/l
—
9
17
62
328
2.52
6.83
3.9
2.6
0.10
0.40
e6/l
2.32
41
234
68
376
2.49
6.81
3.8
2.7
16.46
245.40
e6/l
0.71
49
283
16
26
6.76
6.68
1.1
1.2
65.11
376.33
e6/l
—
9
18
98
645
2.52
6.63
14.0
7.0
2.12
1.91
e9/l
1.38
90
578
122
902
2.95
6.34
9.8
8.6
74.70
77.66
u/l
0.53
122
864
69
415
2.23
5.40
3.4
3.2
9.21
9.00
mmol/l
0.10
64
365
73
451
2.21
5.33
1.9
1.9
94.87
96.76
pmol/l
0.14
36
231
44
221
2.41
5.23
3.2
2.5
590.33
555.73
mosm/kgh2o
0.42
39
196
26
101
2.91
5.14
1.2
1.2
—
—
—
0
0
14
28
5.40
5.09
2.2
3.5
1.13
2.26
index
—
8
16
35
169
2.40
4.48
1.6
2.6
—
—
—
0
0
48
270
2.15
4.27
1.6
1.5
18.61
20.29
nmol/l
0.48
42
233
29
133
2.47
4.13
1.1
1.2
—
—
—
0
0
22
89
2.73
4.02
1.5
1.7
0.14
0.35
mg/l
—
8
42
40
220
2.12
3.72
3.0
3.1
150.62
659.49
ng/l
0.58
29
161
38
209
2.10
3.52
1.8
1.9
2.58
2.91
mg/l
0.42
29
187
29
143
2.28
3.51
1.3
1.9
—
—
—
0
0
126
1058
2.24
3.22
27.2
17.1
13.30
13.40
%
0.38
126
1051
11
30
3.87
3.16
1.4
1.4
194.00
151.29
au/ml
—
5
7
13
48
2.87
2.80
2.1
2.7
—
—
—
0
0
27
142
2.10
2.78
1.4
1.6
—
—
—
0
0
53
352
1.78
2.75
1.9
2.4
—
—
—
0
0
46
293
1.82
2.73
1.5
1.3
0.79
1.18
u/ml
—
8
85
9
28
3.35
2.35
1.1
1.4
219.00
230.64
u/ml
—
9
11
13
55
2.49
2.19
1.3
1.4
—
—
—
0
0
87
695
1.61
2.10
4.8
3.8
—
29.44
—
0
9
40
264
1.70
2.06
1.5
1.4
2.40
2.39
g/l
0.02
20
177
38
248
1.71
2.03
3.3
2.7
—
—
—
0
0
136
1233
2.18
1.98
16.2
14.2
29.50
23.37
mg/l
1.20
114
1007
26
153
1.85
1.96
2.2
2.4
109.44
129.97
ug/g
0.20
21
122
33
210
1.73
1.93
1.6
1.6
—
—
—
0
0
19
101
2.01
1.91
5.3
8.1
1.15
1.29
mmol/l
0.57
19
101
44
599
0.62
1.85
2.4
2.9
—
—
—
0
0
9
35
2.67
1.83
1.0
1.1
—
—
—
0
0
19
104
1.95
1.77
7.0
8.5
—
—
—
0
0
14
68
2.17
1.76
1.4
1.2
—
—
—
0
0
47
340
1.56
1.66
1.4
1.4
—
—
—
0
0
18
105
1.81
1.41
2.0
2.0
—
—
—
0
0
17
98
1.83
1.38
2.0
2.5
0.26
0.23
g/l
0.92
17
89
9
42
2.21
1.36
1.0
1.2
—
—
—
0
0
64
512
1.44
1.35
2.6
2.8
—
—
estimate
—
0
0
18
108
1.76
1.29
2.0
2.0
—
—
—
0
0
13
70
1.94
1.28
5.0
2.6
22.05
24.48
mmol/l
1.87
13
70
14
78
1.88
1.26
1.2
1.2
87.11
373.79
u/ml
0.76
14
68
25
357
0.64
1.22
3.6
3.2
—
—
—
0
0
18
111
1.71
1.18
2.0
1.9
—
—
—
0
0
18
111
1.71
1.18
2.0
1.9
—
—
—
0
0
0
34
0.00
1.17
0.0
2.0
—
7.42
—
0
34
12
65
1.92
1.17
9.8
3.9
154.33
86.50
ng/l
0.65
12
60
20
128
1.65
1.16
1.5
1.4
—
—
—
0
0
127
1171
1.57
1.14
6.9
4.4
5.98
5.92
mmol/l
0.15
122
1092
7
31
2.32
1.12
1.1
1.3
—
—
—
0
0
123
1308
0.66
1.05
12.7
12.1
—
—
—
0
0
5
22
2.32
1.04
1.2
1.0
—
—
—
0
0
97
860
1.37
1.01
3.5
3.6
14.25
14.72
pmol/l
1.06
91
793
35
451
0.71
0.99
3.2
3.2
32.01
40.81
ng/l
0.25
20
292
7
36
1.99
0.98
1.0
1.3
—
—
—
0
0
17
110
1.62
0.95
2.1
1.9
—
—
—
0
0
140
1338
1.77
0.95
25.2
17.1
86.51
79.44
umol/l
0.54
140
1326
17
111
1.60
0.92
7.2
3.4
7.36
7.39
ph
—
10
71
40
316
1.36
0.86
7.6
3.7
7.40
7.39
ph
0.15
25
220
44
353
1.35
0.86
3.9
3.4
58.88
40.07
mg/l
0.19
30
233
0
27
0.00
0.78
0.0
3.6
—
58.69
—
0
27
6
34
1.80
0.77
1.0
3.4
26.67
52.76
u/ml
—
6
34
44
359
1.32
0.77
4.6
4.0
8.99
6.47
mg/mmol
0.14
31
236
36
285
1.35
0.77
2.9
3.7
1.01
1.02
kg/l
1.66
26
186
7
39
1.83
0.73
1.7
1.7
—
4.83
—
0
13
17
118
1.50
0.73
5.1
12.5
96.86
95.84
%
0.70
17
112
134
1284
1.43
0.61
7.9
5.1
2.75
2.82
mmol/l
0.46
128
1214
0
22
0.00
0.60
0.0
1.7
—
8.65
—
0
22
0
22
0.00
0.60
0.0
1.7
—
5.09
—
0
22
0
22
0.00
0.60
0.0
1.7
—
2.50
—
0
14
0
22
0.00
0.60
0.0
1.9
—
—
—
0
0
39
324
1.28
0.59
4.9
5.0
—
—
—
0
0
8
54
1.51
0.58
1.3
1.1
—
—
—
0
0
49
421
1.24
0.56
1.7
1.9
—
—
—
0
0
18
134
1.39
0.56
5.2
11.4
7.40
7.41
ph
—
7
77
9
59
1.56
0.56
2.4
2.3
0.60
0.62
%
—
9
59
9
61
1.51
0.55
2.4
2.3
1.40
1.45
%
—
9
61
19
144
1.37
0.54
1.3
1.2
—
—
—
0
0
56
500
1.19
0.43
7.9
12.0
1.14
1.20
inr
0.35
44
415
5
31
1.63
0.43
2.4
2.4
59.86
63.00
%
—
5
31
17
214
0.77
0.41
1.2
1.2
40.80
25.00
iu/ml
—
7
54
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
4.6
—
3.52
—
0
16
26
310
0.80
0.41
3.9
5.6
—
—
—
0
0
142
1389
1.47
0.41
28.9
20.9
30.63
30.33
pg
1.06
142
1381
142
1389
1.47
0.41
28.9
20.9
90.97
90.25
fl
1.05
142
1381
142
1389
1.47
0.41
29.1
21.1
142.07
142.37
g/l
0.09
142
1380
142
1389
1.47
0.41
29.4
21.3
42.23
42.29
%
0.06
142
1379
0
17
0.00
0.41
0.0
3.8
—
1.17
—
0
11
0
17
0.00
0.41
0.0
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
4.6
—
4.02
—
0
17
0
17
0.00
0.41
0.0
1.5
—
47.94
—
0
17
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
4.9
—
8.26
—
0
19
0
19
0.00
0.39
0.0
2.5
—
46.16
—
0
19
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
126
1216
1.23
0.36
6.2
4.0
1.39
1.37
mmol/l
0.15
119
1147
14
177
0.77
0.35
1.4
1.5
—
—
—
0
0
28
325
0.83
0.34
3.1
2.6
0.62
0.71
ug/l
0.38
19
157
34
386
0.85
0.33
3.2
2.7
0.00
0.00
estimate
—
5
107
131
1272
1.25
0.33
7.5
4.7
4.48
4.66
mmol/l
1.54
125
1207
7
96
0.72
0.32
1.4
1.4
—
—
—
0
0
9
74
1.23
0.26
1.3
1.2
—
—
—
0
0
6
85
0.69
0.24
1.2
1.1
1.45
1.47
g/l
—
6
85
6
85
0.69
0.24
1.2
1.1
1.05
0.87
g/l
—
6
85
130
1269
1.19
0.24
7.6
4.6
1.29
1.35
mmol/l
1.23
124
1201
31
345
0.87
0.23
3.1
3.4
0.00
0.01
estimate
—
7
133
5
42
1.20
0.21
10.6
14.5
0.84
0.82
%
—
5
36
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
4.9
—
73.54
—
0
12
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.26
0.20
9.2
13.0
1.53
1.48
%
—
6
41
0
14
0.00
0.20
0.0
4.5
—
33.00
—
0
14
8
68
1.19
0.17
1.3
1.6
—
—
—
0
0
7
85
0.81
0.15
2.0
1.9
195.71
230.24
pmol/l
—
7
80
47
495
0.93
0.13
3.4
3.2
0.00
0.01
estimate
—
6
116
35
328
1.09
0.12
2.1
2.5
378.86
355.17
umol/l
0.90
35
288
5
44
1.14
0.10
1.2
1.1
—
—
—
0
0
5
44
1.14
0.10
1.2
1.1
—
—
—
0
0
5
46
1.09
0.09
1.6
1.5
5.96
23.07
iu/l
—
5
36
5
64
0.77
0.08
1.4
2.6
213.80
179.40
ng/l
—
5
56
19
181
1.06
0.03
1.2
1.3
1.21
8.07
u/ml
—
9
75
11
102
1.08
0.03
12.3
5.8
9.77
8.78
mmol/l
0.20
11
96
26
262
0.99
0.00
2.2
1.7
0.96
1.06
mg/l
0.13
18
202
6
59
1.02
-0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
3.19
—
0
7
0
6
0.00
-0.00
0.0
9.2
—
0.73
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
235.80
—
0
5
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
3.60
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
9
96
0.93
-0.00
1.1
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
0.31
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
12.80
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
11.99
—
0
7
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
0.00
—
0
8
8
87
0.92
-0.00
1.3
2.2
6.16
6.21
ug/l
—
8
80
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.42
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_SYPHILIS_NOS_WIDE – Other and unspecified syphilis, including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).